Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12188/23690
Title: | Providing clinical evidence under the MDR 2017/745 – new challenges for manufacturers in medical device industry | Authors: | Ivanovska E., Tonic Ribarska J., Lazova J., Popstefanova N., Davcheva Jovanoska M., Trajkovic Jolevska S. | Keywords: | Medical Device Regulation 2017/745 (MDR), Clinical Evaluation, Post-Market Surveillance (PMS), Clinical Investigation (CI), Post-Market Clinical Follow-up (PMCF) | Issue Date: | 2019 | Journal: | Arhiv za farmaciju | Abstract: | Providing necessary clinical evidence throughout the systems for Clinical Evaluation and Post-Market Surveillance in accordance with new MDR 2017/745 requirements imposes new challenges for manufacturers in medical device industry. Manufacturers should make clinical evaluation a continuous process that summarizes findings and results from several mutually connected processes: PMS, vigilance, CIs. Gathered clinical evidence should also be used as input for SSCP, PSUR, CEAR. CIs should be designed, authorised, conducted, recorded and reported in accordance with provisions of Articles 62-81 and Annex XV. PMS and PMCF activities should provide appropriate evidence of planning, implementation of protocol and reporting; target residual risks and confirm safety and performance over device’s lifetime; include activities that address specific questions/residual risks. All activities are aimed towards several goals: improving quality, safety and reliability of devices and strengthening transparency of information for consumers. | Description: | Short communication | URI: | http://hdl.handle.net/20.500.12188/23690 | ISSN: | 2217-8767 |
Appears in Collections: | Faculty of Pharmacy: Journal Articles |
Show full item record
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.